uracil has been researched along with Hematologic Diseases in 8 studies
2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder
Hematologic Diseases: Disorders of the blood and blood forming tissues.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To test the efficacy and safety of pharmacokinetic modulating chemotherapy combined with cisplatin (PMC-cisplatin) as induction chemotherapy (ICT) before definitive treatment in patients with respectable locally advanced head and neck squamous cell carcinoma (HNSCC)." | 2.73 | Effectiveness of pharmacokinetic modulating chemotherapy combined with cisplatin as induction chemotherapy in resectable locally advanced head and neck cancer: phase II study. ( Chang, PM; Chang, SY; Chen, PM; Chu, PY; Huang, JL; Tai, SK; Tsai, TL; Wang, LW; Wang, YF; Yang, MH, 2008) |
| "One patient with colorectal cancer experienced a partial response and 9 patients with non-small cell lung, colorectal and gastro-oesophageal junction carcinomas had disease stabilisation lasting 4-26 (median 6) cycles." | 2.71 | Phase I trial of UFT/leucovorin and irinotecan in patients with advanced cancer. ( Algazy, K; Giantonio, B; Hahn, S; Haller, DG; O'Dwyer, PJ; Redlinger, M; Stevenson, JP; Sun, W; Thorn, C; Vaughn, D; Veronese, ML; Whitehead, AS, 2004) |
| " The most appropriate dosing option appeared to be 400 mg x m(-2) per day of oral UFT for 14 consecutive days with 900 mg x m(-2) gemcitabine on days 8 and 15." | 2.70 | A phase I study of combination chemotherapy with gemcitabine and oral UFT for advanced non-small cell lung cancer. ( Asoh, H; Ichinose, Y; Semba, H; Seto, T; Yamamoto, H; Yoh, K, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (25.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (75.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Overman, MJ | 1 |
| Kopetz, S | 1 |
| Varadhachary, G | 1 |
| Fukushima, M | 1 |
| Kuwata, K | 1 |
| Mita, A | 1 |
| Wolff, RA | 1 |
| Hoff, P | 1 |
| Xiong, H | 1 |
| Abbruzzese, JL | 1 |
| PETROV, KIa | 1 |
| Veronese, ML | 1 |
| Stevenson, JP | 1 |
| Sun, W | 1 |
| Redlinger, M | 1 |
| Algazy, K | 1 |
| Giantonio, B | 1 |
| Hahn, S | 1 |
| Vaughn, D | 1 |
| Thorn, C | 1 |
| Whitehead, AS | 1 |
| Haller, DG | 1 |
| O'Dwyer, PJ | 1 |
| Kim, SJ | 1 |
| Seo, HY | 1 |
| Choi, JG | 1 |
| Sul, HR | 1 |
| Sung, HJ | 1 |
| Park, KH | 1 |
| Choi, IK | 1 |
| Oh, SC | 1 |
| Yoon, SY | 1 |
| Seo, JH | 1 |
| Choi, CW | 1 |
| Kim, BS | 1 |
| Shin, SW | 1 |
| Kim, YH | 1 |
| Kim, JS | 1 |
| Chang, PM | 1 |
| Chen, PM | 1 |
| Chu, PY | 1 |
| Wang, LW | 1 |
| Tai, SK | 1 |
| Tsai, TL | 1 |
| Huang, JL | 1 |
| Wang, YF | 1 |
| Chang, SY | 1 |
| Yang, MH | 1 |
| Vestermark, LW | 1 |
| Jacobsen, A | 1 |
| Qvortrup, C | 1 |
| Hansen, F | 1 |
| Bisgaard, C | 1 |
| Baatrup, G | 1 |
| Rasmussen, P | 1 |
| Pfeiffer, P | 1 |
| Seto, T | 1 |
| Yoh, K | 1 |
| Asoh, H | 1 |
| Yamamoto, H | 1 |
| Semba, H | 1 |
| Ichinose, Y | 1 |
| Kholodnyi, MD | 1 |
| Mindlin, SS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Trial of TAS-102 in Patients With Advanced, Refractory Pancreatic Adenocarcinoma[NCT04923529] | Phase 2 | 28 participants (Anticipated) | Interventional | 2021-03-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 trials available for uracil and Hematologic Diseases
| Article | Year |
|---|---|
Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neopl | 2008 |
Phase I trial of UFT/leucovorin and irinotecan in patients with advanced cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dos | 2004 |
Phase II study with a combination of epirubicin, cisplatin, UFT, and leucovorin in advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antidotes; Antineoplastic Agents; Antineoplastic Combined | 2006 |
Effectiveness of pharmacokinetic modulating chemotherapy combined with cisplatin as induction chemotherapy in resectable locally advanced head and neck cancer: phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2008 |
Long-term results of a phase II trial of high-dose radiotherapy (60 Gy) and UFT/l-leucovorin in patients with non-resectable locally advanced rectal cancer (LARC).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Comb | 2008 |
A phase I study of combination chemotherapy with gemcitabine and oral UFT for advanced non-small cell lung cancer.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cel | 2002 |
2 other studies available for uracil and Hematologic Diseases
| Article | Year |
|---|---|
[On dopan therapy of patients with lymphogranulomatosis, chronic lymphatic leukemia and other systemic blood diseases].
Topics: Antineoplastic Agents; Hematologic Diseases; Hodgkin Disease; Humans; Leukemia; Leukemia, Lymphocyti | 1961 |
[The hypoplastic state of hematopoiesis following chemotherapy with alkylating compounds].
Topics: Adult; Aged; Alkylating Agents; Antineoplastic Agents; Breast Neoplasms; Female; Hematologic Disease | 1969 |